<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xml:base="http://www.fiercepharma.com" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
 <title>Accupril</title>
 <link>http://www.fiercepharma.com/tags/accupril</link>
 <description></description>
 <language>en</language>
<item>
 <title>ALSO NOTED:  Teva&#039;s Accupril gets FDA OK; Elder Pharmaceuticals buys Biomeda;</title>
 <link>http://www.fiercepharma.com/story/also-noted-tevas-accupril-gets-fda-ok-elder-pharmaceuticals-buys-biomeda/2007-08-28?utm_medium=rss&amp;utm_source=rss&amp;cmp-id=OTC-RSS-FP0</link>
 <description>&lt;p&gt;
&amp;gt; Teva has nabbed an OK from the FDA for its generic form of Accupril, Pfizer&#039;s high blood pressure remedy. Total U.S. sales of the drug--branded and generic forms--amounted to $150 million for the 12 months ended June 30. &lt;a href=&quot;http://www.fiercebiotech.com/press-releases/press-release-teva-announces-approval-generic-accupril-tablets&quot;&gt;Release&lt;/a&gt;
&lt;/p&gt;
&lt;p&gt;
&amp;gt; Indian drug maker Elder Pharmaceuticals has agreed to buy Bulgaria&#039;s Biomeda Group for €10 million in cash. It&#039;s Elder&#039;s second acquisition in two months; the company hopes to use Biomeda as leverage for more European product launches. &lt;a href=&quot;http://www.business-standard.com/common/storypage_c_online.php?leftnm=11&amp;amp;bKeyFlag=IN&amp;amp;autono=26999&quot;&gt;Report&lt;/a&gt;
&lt;/p&gt;
&lt;p&gt;
&amp;gt; Medical laser-maker Candela got a new indication from the FDA for its Serenity device, used to reduce pain during pulsed-light and laser treatments. &lt;a href=&quot;http://www.reuters.com/article/health-SP/idUSWNAS298820070828&quot;&gt;Report&lt;/a&gt;
&lt;/p&gt;
&lt;p&gt;
&lt;strong&gt;And Finally... &lt;/strong&gt;Low-dose products for menopause treatment have flooded the market with since the Women&#039;s Health Initiative found that hormone therapy could be harmful. But there&#039;s no research proving low doses are safer than traditional products. &lt;a href=&quot;http://www.nytimes.com/2007/08/28/health/28cons.html?_r=1&amp;amp;oref=slogin&quot;&gt;Article&lt;/a&gt;
&lt;/p&gt;
</description>
 <comments>http://www.fiercepharma.com/story/also-noted-tevas-accupril-gets-fda-ok-elder-pharmaceuticals-buys-biomeda/2007-08-28#comments</comments>
 <category domain="http://www.fiercepharma.com/tags/accupril">Accupril</category>
 <category domain="http://www.fiercepharma.com/tags/bimeda-groups">Bimeda Groups</category>
 <category domain="http://www.fiercepharma.com/tags/candela">Candela</category>
 <category domain="http://www.fiercepharma.com/tags/elder-pharmaceuticals">Elder Pharmaceuticals</category>
 <category domain="http://www.fiercepharma.com/tags/fda">FDA</category>
 <category domain="http://www.fiercepharma.com/tags/pfizer">Pfizer</category>
 <category domain="http://www.fiercepharma.com/tags/teva">Teva</category>
 <pubDate>Tue, 28 Aug 2007 06:59:50 -0400</pubDate>
 <dc:creator />
 <guid isPermaLink="false">7713 at http://www.fiercepharma.com</guid>
</item>
</channel>
</rss>
